Boehringer Ingelheim Animal Health has ceased the production of TRODAX® 340 mg/ml Solution for Injection, containing nitroxynil, for the European market.
Cattle and sheep farmers use TRODAX® to treat the mature and late-immature stages of the liver fluke Fasciola hepatica.
The flukicide product is also indicated for the treatment of Haemonchus contortus infections.
The animal health company issued a statement earlier this morning (Friday, September 17th, 2021).
Findlay MacBean, business head for ruminant, at Boehringer Ingelheim Animal Health, said:
“TRODAX® is a well-regarded flukicide, and has been used successfully for many years by cattle and sheep producers.”
“Manufacturing problems have led to TRODAX® being out of stock since late 2020.”
“It is with regret that we have to confirm that we are no longer able to manufacture the product.”
“As one of the largest animal health businesses in the world, we are committed to improving the lives and health of animals.”
“We have a strong research and development focus and a pipeline of potential products, including antiparasitics.”
“We recognise that the discontinuation of TRODAX® may pose challenges for cattle and sheep producers, particularly in instances where resistance to other flukicides has been confirmed.”
The company advises impacted farmers to review their fluke control plan with a vet or animal health advisor.
Furthermore, this change will not impact Boehringer Ingelheim Animal Health’s other wormer and flukicide brands.
IVOMEC® Super Injection contains ivermectin and clorsulon and provides an alternative treatment option for adult liver fluke in cattle.
Also, it is effective against gastrointestinal worm species, lungworms, and key external parasites.
That's Farming Latest Farming News All In One Place
© 2022. ThatsFarming. All Rights Reserved. Website Design by Agile Digital Strategy.